期刊文献+

胰腺癌病人如何选择辅助治疗

下载PDF
导出
摘要 二十多年前,主流观点认为胰腺癌术后辅助治疗不能改善病人的生存期。第一个术后辅助治疗的前瞻性对照研究是1985年的GITSG研究,此后欧洲和美国先后组织了一系列临床研究,包括EORTC、ESPAC-1、RTOG-9704、CONCO-001等.今年的ASCO年会上发布了最新的ESPAC-3研究结果。上述研究均证实.胰腺癌切除术后辅助治疗可改善胰腺癌病人的生存期。但对于胰腺癌术后最佳的辅助治疗方案.跨大西洋两岸的观点始终不一致,美国倾向于先予联合放化疗,随后化疗;欧洲则以化疗为主。
作者 楼文晖
出处 《外科理论与实践》 2009年第5期549-552,共4页 Journal of Surgery Concepts & Practice
  • 相关文献

参考文献26

  • 1Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection[J]. Arch Surg, 1985,120(8):899-903.
  • 2Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase Ⅰ-Ⅱ trial of the EORTC gastrointestinal tract cancer cooperative group[J]. Ann Surg, 1999,230(6):776-782.
  • 3Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12):1200-1210.
  • 4Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase Ⅲ study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma[J]. J Clin Oncol, 2006,24(18S):1802.
  • 5Bakkevold KE, Arnesjφ B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study [J]. Eur J Cancer, 1993,29A(5):698-703.
  • 6Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J]. Cancer, 2002,95(8):1685-1695.
  • 7Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer[J]. Br J Cancer, 2005,92(8):1372-1381.
  • 8Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer, a randomized controlled trial[J]. JAMA, 2007,297(3):267-277.
  • 9Kang SP, Sail MW. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?[J]. JOP, 2008,9(2):83-90.
  • 10Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [J]. J Clin Oncol, 2008,26(20 suppl):4508.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部